Bharat Immunologicals & Biologicals Corporation Limited (BSE: 524663)
Health Care · Biotechnology · IN
Rs15.80
-1.86% today · -30.2% 1Y
Bharat Immunologicals & Biologicals Corporation Limited (BSE: 524663) operates in the Biotechnology industry within the Health Care sector. The company is valued at $7.13M.
Over the last twelve months the share price has lost 30.2%, trading between 14.10 and 23.14.
Tweenvest scores Bharat Immunologicals & Biologicals Corporation Limited across four factors: quality 48/100, value 42/100, growth 0/100. Its strongest factor is quality.
524663 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $7.13M
- Revenue (TTM)
- $920.80K
- P/E
- —
- EPS
- -4.28
- Dividend yield
- —
- Beta (5Y)
- 0.42
- 52-week high
- Rs23.14
- 52-week low
- Rs14.10
- Avg volume (3M)
- —
- Shares outstanding
- 43.18M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.39 | +0.23% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.95 | -0.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $147.78 | -0.67% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $548.74 | -0.74% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $827.02 | -0.78% |
| argenx SEENXTBR: ARGX | $64.17B | €895.40 | +1.84% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $155.61 | -2.03% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.